AstraZeneca taps Isis for antisense R&D; Dendreon's struggles loom large in cancer vax R&D;

@FierceBiotech: AstraZeneca trumpets a preclinical long shot in bid to burnish Brilinta's prospects. More | Follow @FierceBiotech

@JohnCFierce: Oxigene's positive PhII ovarian cancer data faces analyst's skepticism. More | Follow @JohnCFierce

@DamianFierce: Top-notch brand synergy here. Nothing says "trustworthy" like a pawnbroker. Picture | Follow @DamianFierce

> AstraZeneca ($AZN) has expanded its alliance with Isis Pharmaceuticals ($ISIS), teaming up to develop new delivery methods for oligonucleotide therapies. The two have been working together since 2012 on antisense therapies for cancer and cardiovascular and metabolic diseases. More

> Merck ($MRK) has signed a deal to collaborate with Belgium's Euroscreen on some undisclosed drug targets, an agreement that puts the latter company in line for more than €100 million ($125 million) in milestone payments. News

> Dendreon's ($DNDN) slow march to oblivion has cast a pall over the field of cancer vaccine development. Story

Medical Device News

@FierceMedDev: Medtronic borrows $16B to cover rising costs of Covidien deal. More | Follow @FierceMedDev

@VarunSaxena2: Xerox invests in HealthSpot, a telemedicine provider. More | Follow @VarunSaxena2

@EmilyWFierce: First pharma swag submission of the day: Flonase wristwatch. Feel free to send pics to [email protected]Picture | Follow @EmilyWFierce

> Congressional Republicans move full speed ahead to nix medical device tax. Story

> Glooko merges tech data to avoid activity-triggered hypoglycemic events. Article

> Consultant says Sunshine Act leads to implicit coordination of payments to docs. Article

Pharma News

@FiercePharma: Merck JV signs on Bangladeshi firms to speed low-cost cholera candidate. More | Follow @FiercePharma

@EricPFierce: Cadila gets slapped with #FDA warning for not following up on complaints about stinking APIs. Story | Follow @EricPFierce

@CarlyHFierce: At long last, Sanofi launches low-cost pentavalent in India. More | Follow @CarlyHFierce

> FDA to Mallinckrodt: Generic Concerta doesn't measure up to J&J's brand. News

> U.K. unveils top cancer brands facing yea-or-nay for CDF funding. Article

> Merck KGaA bucks up on Rebif sales, emerging markets growth. Story

Vaccines News

> Report: Sanofi has billion-dollar dengue opportunity in India. Item

> U.K. pols press PM Cameron on Bexsero coverage delay. Story

> Study: Universal E. coli vaccine appears possible thanks to limited number of strains. Report

> At long last, Sanofi launches low-cost pentavalent in India. More

> Merck JV signs on Bangladeshi firms to speed low-cost cholera candidate. Story

> Dendreon bankruptcy weighs on cancer vaccine field. Article

Pharma Manufacturing News

> Consort's Aesica buyout sets it up to jointly develop drugs and delivery devices. Story

> Sun's deal to buy Ranbaxy faces delays. Article

> Spain's Exeltis gets two plants in Turkey with deal for Embil. More

> Neopharma to build plant in Saudi Arabia. Story

> Police probe wholesalers for selling subsidized drugs outside of Spain. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.